To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 513 participants.

Also called NCT05699408

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 513 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05699408
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05699408. Randomized; no masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-11-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
Intervention (Drug)
INS068 injection
Intervention (Drug)
Insulin Glargine
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05699408
Content hash
da3e081e348b468b76ee7ef5e84a3ad85913e12003b243f88446a40e72511e88